HEICO (HEI-A) Is At $60.95 Formed Wedge; Conformis (CFMS) Shorts Raised By 18.25%

Conformis, Inc. (NASDAQ:CFMS) Logo

HEICO Corporation (HEI-A) formed wedge up with $62.78 target or 3.00% above today’s $60.95 share price. HEICO Corporation (HEI-A) has $7.04B valuation. The stock increased 0.08% or $0.05 during the last trading session, reaching $60.95. About 291,823 shares traded or 74.09% up from the average. HEICO Corporation (NYSE:HEI.A) has risen 52.26% since July 1, 2017 and is uptrending. It has outperformed by 39.69% the S&P500.

Conformis Inc (NASDAQ:CFMS) had an increase of 18.25% in short interest. CFMS’s SI was 2.97 million shares in July as released by FINRA. Its up 18.25% from 2.51M shares previously. With 444,800 avg volume, 7 days are for Conformis Inc (NASDAQ:CFMS)’s short sellers to cover CFMS’s short positions. The SI to Conformis Inc’s float is 7.44%. The stock increased 0.81% or $0.01 during the last trading session, reaching $1.25. About 152,190 shares traded. Conformis, Inc. (NASDAQ:CFMS) has declined 70.00% since July 1, 2017 and is downtrending. It has underperformed by 82.57% the S&P500. Some Historical CFMS News: 07/03/2018 – CONFORMIS: ITOTAL CR KNEE IMPLANT REVISION RATE 0.5% IN STUDY; 07/03/2018 Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR; 02/05/2018 – ConforMIS 1Q Loss $12M; 02/05/2018 – CONFORMIS 1Q LOSS/SHR 22C, EST. LOSS/SHR 25C; 02/05/2018 – ConforMIS 1Q Loss/Shr 22c; 02/05/2018 – ConforMIS 1Q Rev $19.7M; 21/04/2018 – DJ ConforMIS Inc, Inst Holders, 1Q 2018 (CFMS); 19/04/2018 – Smith & Nephew Inc. vs ConforMIS, Inc. | FWD Entered | 04/19/2018; 26/04/2018 – Emerald Mutual Advisers Trust Buys 1.3% Position in Conformis; 02/05/2018 – CONFORMIS 1Q REV. $19.7M, EST. $19.6M

ConforMIS, Inc., a medical technology company, develops, makes, and sells customized joint replacement implants. The company has market cap of $76.14 million. The firm offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product for treatment of the medial or lateral compartment of the knee, as well as provides iJigs, customized single-use patient-specific instruments. It currently has negative earnings. It is also developing iTotal Hip, a customized total hip replacement implant.

Another recent and important Conformis, Inc. (NASDAQ:CFMS) news was published by Nasdaq.com which published an article titled: “Peer Reviewed Results: Conformis Patient Specific iTotal CR Achieves Better Rotational Alignment and Tibial Fit …” on June 25, 2018.

Among 3 analysts covering ConforMIS (NASDAQ:CFMS), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. ConforMIS had 4 analyst reports since January 2, 2018 according to SRatingsIntel. JP Morgan downgraded the shares of CFMS in report on Tuesday, January 2 to “Underweight” rating. Canaccord Genuity upgraded the stock to “Buy” rating in Tuesday, April 10 report. The stock has “Hold” rating by Canaccord Genuity on Thursday, February 8.

Conformis, Inc. (NASDAQ:CFMS) Ratings Chart